CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles' Heel?

Leonardo M R Ferreira; Yannick D Muller

doi:10.3389/fimmu.2021.766220

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles' Heel?

Front Immunol. 2021 Nov 17:12:766220. doi: 10.3389/fimmu.2021.766220. eCollection 2021.

Authors

Leonardo M R Ferreira^{1

2}, Yannick D Muller³

Affiliations

¹ Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States.
² Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.
³ Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

No abstract available

Keywords: CD19 CAR T-cell; CD28; chimeric antigen receptor; cytokine release syndrome; heterodimerization; immune effector cell-associated neurotoxicity syndrome; neurotoxicity; transmembrane domain.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
CD28 Antigens
Dimerization
Humans
Immunotherapy, Adoptive / adverse effects*
Receptors, Chimeric Antigen*

Substances

CD28 Antigens
Receptors, Chimeric Antigen